Phillip F. Pierce Source Confirmed

OverviewAI-generated summary

Phillip F. Pierce's research has focused on the efficacy and safety of novel pharmacological agents for managing neuropathic pain, particularly in the context of diabetic peripheral neuropathy. His publications include studies on LX9211, an orally-administered, non-opioid AAK1 inhibitor, investigating its potential for pain relief in conditions such as painful diabetic peripheral neuropathy. Pierce has also been involved in research on pilavapadin, another oral, non-opioid AAK1 inhibitor, for diabetic peripheral neuropathic pain, with results presented from Phase 2b studies.

In addition to pharmacological research, Pierce has contributed to the development and evaluation of digital health tools. This includes a reliability study for SOBER-EYE, a mobile application designed to assess pupillary light reflex. His work in this area suggests an interest in utilizing technology for objective health assessments. Pierce's scholarship metrics include an h-index of 24, with 58 total publications and over 2,000 citations, indicating a significant body of work in his research areas. He maintains an active lab website, suggesting ongoing research activities.

Metrics

• h-index: 24
• Publications: 58
• Citations: 2,089